Physician profile
Michael G Bodnar
NPI 1740296698
$4,840.12
in general payments reported to CMS, 2019-2025
25 companies · $964 in 2025
The $964 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $289 · 2020: $482 · 2021: $79.29 · 2022: $627 · 2023: $1,028 · 2024: $1,371 · 2025: $964.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,197 · Education: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,197.25 |
| Education | $165.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $890.96 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $837.35 | 2019-2025 | Dupixent |
| Abbvie INC. | $476.87 | 2022-2025 | Skyrizi, Rinvoq |
| Galderma Laboratories, L.P. | $419.98 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Janssen Biotech, INC. | $419.05 | 2021-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $277.56 | 2020-2025 | Ilumya |
| Leo Pharma INC. | $258.41 | 2022-2025 | Adbry, Anzupgo |
| Pfizer INC. | $231.81 | 2021-2025 | |
| Amgen INC. | $215.34 | 2022-2025 | Otezla, Otezla |
| Lilly USA, LLC | $180.28 | 2022-2025 | Ebglyss, Olumiant, Taltz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $114.09 | 2020-2024 | Jublia, Arazlo, Cabtreo |
| Novartis Pharmaceuticals Corporation | $89.92 | 2022-2025 | |
| Ucb, INC. | $82.74 | 2024 | Bimzelx |
| Mayne Pharma Commercial LLC | $56.81 | 2023-2024 | |
| Biofrontera INC. | $46.42 | 2019-2023 | Xepi, Bf-Rhodoled, Ameluz |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $46.21 | 2023-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $38.17 | 2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $26.81 | 2024 | Sotyktu |
| Almirall LLC | $23.16 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.72 | 2023 | Spevigo |
| Vyne Pharmaceuticals INC. | $22.47 | 2021 | |
| Organogenesis INC. | $22.45 | 2019 | |
| Lnhc, INC | $14.18 | 2025 | Zelsuvmi |
| Botanix Sb INC | $14.04 | 2025 | Sofdra |
| Epi Health, LLC | $12.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bodnar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.